Prothena Corporation plc Stock News

U.S. stocks traded mixed this morning, with the Dow Jones gaining around 20 points on Wednesday. The Dow traded up 0.07% to 29,154.99 while the NASDAQ fell 0.23% to 10,804.74. The S&P 500 also rose, g

Upgrades According to B of A Securities, the prior rating for Prothena Corp PLC (NASDAQ:PRTA) was changed from Neutral to Buy. Prothena Corp earned $0.88 in the second quarter, compared to $0.58 in th

Source: Atthapon Raksthaput / Shutterstock.com Prothena (NASDAQ: PRTA ) stock is seeing massive gains on Wednesday despite a lack of news from the late-stage clinical company. However, there is news f

Positive results for Biogen's Alzheimer's disease candidate are boosting all three stocks.

Gainers Atlis Motor Vehicles Inc (NASDAQ: AMV) rose 211.7% to $256.00 in pre-market trading after jumping around 199% on Tuesday. Silo Pharma, Inc. (NASDAQ: SILO) rose 105% to $10.46 in pre-market tr

U.S. stock futures traded lower this morning. Here are some big stocks moving higher in today’s pre-market trading session. Biogen Inc. (NASDAQ: BIIB) shares rose 39.7% to $276.32 in pre-market tra

Prothena (PRTA) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built o

DUBLIN, Ireland, Sept. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built o

Prothena (PRTA) incurs a loss in the second quarter while revenues miss estimates.

Prothena (PRTA) incurs a loss in the second quarter while revenues miss estimates.

Prothena (PRTA) delivered earnings and revenue surprises of -72.55% and 93.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Prothena (PRTA) delivered earnings and revenue surprises of -72.55% and 93.48%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

DUBLIN, Ireland, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on

DUBLIN, Ireland, Aug. 01, 2022 (GLOBE NEWSWIRE) -- Prothena Corporation plc (NASDAQ:PRTA), a late-stage clinical biotechnology company with a robust pipeline of investigational therapeutics built on p